{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T17:38:17Z","timestamp":1771522697681,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273840"],"award-info":[{"award-number":["82273840"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073754"],"award-info":[{"award-number":["82073754"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.intimp.2025.116114","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T16:25:03Z","timestamp":1767457503000},"page":"116114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Leveraging SARS-CoV-2-induced pre-existing humoral and cellular immunity for tumor elimination"],"prefix":"10.1016","volume":"171","author":[{"given":"Lingxiao","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiumin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shukang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuli","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangdong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"34","key":"10.1016\/j.intimp.2025.116114_bb0005","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody Pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2025.116114_bb0010","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with Pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.intimp.2025.116114_bb0015","first-page":"2656","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in","volume":"39","author":"Sarnaik","year":"2021","journal-title":"Metastatic Melanoma. J Clin Oncol"},{"key":"10.1016\/j.intimp.2025.116114_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.680407","article-title":"Immunotherapy in Acral and mucosal melanoma: current status and future directions","volume":"12","author":"Mao","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12382","article-title":"Enhancement of T cell recruitment and infiltration into tumours","volume":"178","author":"Oelkrug","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13046-024-02960-w","article-title":"T-cell infiltration and its regulatory mechanisms in cancers: insights at single-cell resolution","volume":"43","author":"Yang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7706","key":"10.1016\/j.intimp.2025.116114_bb0040","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0045","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41467-019-08534-1","article-title":"Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy","volume":"10","author":"Rosato","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2025.116114_bb0050","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s43018-022-00335-8","article-title":"Bystander T cells in cancer immunology and therapy","volume":"3","author":"Meier","year":"2022","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12943-022-01574-0","article-title":"Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8(+) T cells for cancer immunotherapy","volume":"21","author":"Jung","year":"2022","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2025.116114_bb0060","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41587-019-0404-8","article-title":"Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy","volume":"38","author":"Millar","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.intimp.2025.116114_bb0065","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.trecan.2016.10.010","article-title":"B lymphocytes and cancer: a love-hate relationship","volume":"2","author":"Yuen","year":"2016","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2025.116114_bb0070","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","article-title":"B cells in the tumor microenvironment: multi-faceted organizers, regulators, and effectors of anti-tumor immunity","volume":"41","author":"Laumont","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2025.116114_bb0075","doi-asserted-by":"crossref","first-page":"1083462","DOI":"10.3389\/fimmu.2022.1083462","article-title":"Focusing on NK cells and ADCC: a promising immunotherapy approach in targeted therapy for HER2-positive breast cancer","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.intimp.2025.116114_bb0080","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1158\/1078-0432.CCR-20-0768","article-title":"Phase I trial of expanded, activated autologous NK-cell infusions with Trastuzumab in patients with HER2-positive cancers","volume":"26","author":"Lee","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.116114_bb0085","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/1078-0432.CCR-16-0970","article-title":"TNF\u03b1-induced mucin 4 expression elicits Trastuzumab resistance in HER2-positive breast Cancer","volume":"23","author":"Mercogliano","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/imr.13089","article-title":"Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines","volume":"310","author":"Sette","year":"2022","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.intimp.2025.116114_bb0095","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-Centre, double-blind, randomised, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0100","doi-asserted-by":"crossref","first-page":"e1072","DOI":"10.1093\/cid\/ciab884","article-title":"One-year sustained cellular and humoral immunities in coronavirus disease 2019 (COVID-19) convalescents","volume":"75","author":"Zhang","year":"2022","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2025.116114_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098856","article-title":"The need for randomization in animal trials: an overview of systematic reviews","volume":"9","author":"Hirst","year":"2014","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.intimp.2025.116114_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16091144","article-title":"Comparative efficacy of animal depression models and antidepressant treatment: a systematic review and Meta-analysis","volume":"16","author":"Ratajczak","year":"2024","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.intimp.2025.116114_bb0115","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/cyto.a.24969","article-title":"Transparency and reporting in the evaluation of PD1 by flow cytometry","volume":"107","author":"Sorigue","year":"2025","journal-title":"Cytometry A"},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0120","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1038\/s41467-021-25589-1","article-title":"Sequences in the cytoplasmic tail of SARS-CoV-2 spike facilitate expression at the cell surface and syncytia formation","volume":"12","author":"Cattin-Ortol\u00e1","year":"2021","journal-title":"Nat. Commun."},{"issue":"6710","key":"10.1016\/j.intimp.2025.116114_bb0125","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1126\/science.adn5658","article-title":"Structure and inhibition of SARS-CoV-2 spike refolding in membranes","volume":"385","author":"Grunst","year":"2024","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0008-8749(87)90297-8","article-title":"Simultaneous development of antibody-dependent cellular cytotoxicity (ADCC) and natural killer (NK) activity in irradiated mice reconstituted with bone marrow cells","volume":"109","author":"Sihvola","year":"1987","journal-title":"Cell. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2025.116114_bb0135","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1002\/hep.30528","article-title":"An efficient combination immunotherapy for primary liver Cancer by harmonized activation of innate and adaptive immunity in mice","volume":"69","author":"Wen","year":"2019","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.intimp.2025.116114_bb0140","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.4049\/jimmunol.161.7.3400","article-title":"IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production","volume":"161","author":"Yoshimoto","year":"1998","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.immuni.2017.11.025","article-title":"Innate-like cytotoxic function of bystander-activated CD8(+) T cells is associated with liver injury in acute hepatitis a","volume":"48","author":"Kim","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0150","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.1038\/s41467-019-12980-2","article-title":"CXCR3 enables recruitment and site-specific bystander activation of memory CD8(+) T cells","volume":"10","author":"Maurice","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.116114_bb0155","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"suppl_12","key":"10.1016\/j.intimp.2025.116114_bb0160","article-title":"Mechanisms regulating T-cell infiltration and activity in solid tumors","volume":"28","author":"Lanitis","year":"2017","journal-title":"Ann. Oncol."},{"issue":"26","key":"10.1016\/j.intimp.2025.116114_bb0165","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116738119","article-title":"Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors","volume":"119","author":"\u00c7uburu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.intimp.2025.116114_bb0170","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial","volume":"50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.intimp.2025.116114_bb0175","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.immuni.2020.10.006","article-title":"Unbiased screens show CD8(+) T cells of COVID-19 patients recognize shared epitopes in SARS-CoV-2 that largely reside outside the spike protein","volume":"53","author":"Ferretti","year":"2020","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0180","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41467-021-22811-y","article-title":"Identification and characterization of a SARS-CoV-2 specific CD8(+) T cell response with immunodominant features","volume":"12","author":"Gangaev","year":"2021","journal-title":"Nat. Commun."},{"issue":"39","key":"10.1016\/j.intimp.2025.116114_bb0185","doi-asserted-by":"crossref","first-page":"24384","DOI":"10.1073\/pnas.2015486117","article-title":"Suboptimal SARS-CoV-2-specific CD8(+) T cell response associated with the prominent HLA-A*02:01 phenotype","volume":"117","author":"Habel","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.intimp.2025.116114_bb0190","doi-asserted-by":"crossref","DOI":"10.1172\/JCI145476","article-title":"SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals","volume":"131","author":"Kared","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"25","key":"10.1016\/j.intimp.2025.116114_bb0195","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1182\/blood.2020008488","article-title":"SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein","volume":"136","author":"Keller","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2025.116114_bb0200","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202617","article-title":"Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection","volume":"218","author":"Le Bert","year":"2021","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0205","doi-asserted-by":"crossref","first-page":"13164","DOI":"10.1038\/s41598-021-92521-4","article-title":"Immunodominant T-cell epitopes from the SARS-CoV-2 spike antigen reveal robust pre-existing T-cell immunity in unexposed individuals","volume":"11","author":"Mahajan","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","article-title":"SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition","volume":"22","author":"Nelde","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2025.116114_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103410","article-title":"SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity","volume":"68","author":"Nielsen","year":"2021","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.intimp.2025.116114_bb0220","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","article-title":"Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19","volume":"21","author":"Peng","year":"2020","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0225","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.11.029","article-title":"Functional SARS-CoV-2-specific immune memory persists after mild COVID-19","volume":"184","author":"Rodda","year":"2021","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.intimp.2025.116114_bb0230","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.1172\/JCI140965","article-title":"SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition","volume":"130","author":"Sattler","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0235","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41591-020-01143-2","article-title":"Characterization of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells","volume":"27","author":"Schulien","year":"2021","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0240","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","article-title":"Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19","volume":"183","author":"Sekine","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.intimp.2025.116114_bb0245","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.immuni.2020.11.004","article-title":"SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors","volume":"53","author":"Shomuradova","year":"2020","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2025.116114_bb0250","article-title":"Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"issue":"7867","key":"10.1016\/j.intimp.2025.116114_bb0255","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"issue":"7821","key":"10.1016\/j.intimp.2025.116114_bb0260","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0265","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/22221751.2022.2056524","article-title":"A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates","volume":"11","author":"An","year":"2022","journal-title":"Emerg Microbes Infect"},{"issue":"10127","key":"10.1016\/j.intimp.2025.116114_bb0270","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.intimp.2025.116114_bb0275","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1161\/CIRCULATIONAHA.123.065438","article-title":"MicroRNA-122-mediated liver Detargeting enhances the tissue specificity of cardiac genome editing","volume":"149","author":"Yang","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.intimp.2025.116114_bb0280","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1186\/s12967-024-05599-5","article-title":"AAV-DJ is superior to AAV9 for targeting brain and spinal cord, and de-targeting liver across multiple delivery routes in mice","volume":"22","author":"Chauhan","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2025.116114_bb0285","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.omtm.2023.06.002","article-title":"Innate and adaptive AAV-mediated immune responses in a mouse model of Duchenne muscular dystrophy","volume":"30","author":"Emami","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"10.1016\/j.intimp.2025.116114_bb0290","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.intimp.2025.116114_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26020816","article-title":"Challenges in humoral immune response to adeno-associated viruses determination","volume":"26","author":"Naumova","year":"2025","journal-title":"Int. J. Mol. Sci."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925021034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925021034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:57:43Z","timestamp":1771520263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925021034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":59,"alternative-id":["S1567576925021034"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.116114","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging SARS-CoV-2-induced pre-existing humoral and cellular immunity for tumor elimination","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.116114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116114"}}